Abstract 449P
Background
Improved cancer survival rates have escalated the demand for sustainable supportive care for survivors. Nasopharyngeal cancer (NPC) survivors often grapple with lasting radiation side effects. The M. D. Anderson Symptom Inventory - Head & Neck Module - Chinese version (MDASI-HN-C) has previously been validated for NPC patients undergoing radiation therapy (RT), but not for survivors. This study aims to psychometrically validate the MDASI-HN-C for NPC survivors.
Methods
In this single-centre cross-sectional study, 200 NPC survivors who completed RT with or without chemotherapy between three and 120 months were surveyed. The internal consistency reliability, convergent, and construct validity of the MDASI-HN-C were evaluated using Cronbach’s alpha (α) test, Pearson’s correlation (r), and exploratory factor analysis (EFA), respectively.
Results
All three subscales of the MDASI-HN-C exhibited strong internal consistency, with α ranging from 0.855 to 0.911. The MDASI-HN-C subscales were negatively correlated with the total score (r = -0.538 to -0.612; all p < 0.001), physical (r = -0.679 to -0.787; all p < 0.001), emotional (r = -0.536 to -0.625; all p < 0.001), functional (r = -0.307 to -0.390; all p < 0.001), and HN-specific (r = -0.587 to -0.616; all p < 0.001) domains of the Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) scale. No correlations were identified between any subscales and the social/family domain. The MDASI-HN-C subscales were also positively correlated with the total score of the Cancer Survivors’ Unmet Needs Measure (CaSUN) (r = 0.414 to 0.468; all p < 0.001). Two factors for the 13 core items were identified by EFA, while only one factor each was found for the HN-specific and interference items. Noteworthily, open-ended responses indicated significant concerns about hearing loss and tinnitus among NPC survivors.
Conclusions
The MDASI-HN-C is a robust tool with satisfactory psychometric properties for assessing symptom burden among NPC survivors. The inclusion of 'hearing problems' as an additional item would enhance its applicability by capturing sensorial disturbances that significantly affect this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract